Doxorubicin-induced Cardiotoxicity and Cardioprotective Agents: Classic and New Players in the Game
Autor: | Liliana Borges de Menezes, Marina Pacheco Miguel, Mara Rúbia Nunes Celes, Fernanda Dias Tomé, Patrícia Resende Alo Nagib, Danilo Figueiredo Soave, Felipe Dos Santos Arruda, Erica C. Campos |
---|---|
Rok vydání: | 2019 |
Předmět: |
Cardiotonic Agents
Apoptosis macromolecular substances Pharmacology medicine.disease_cause 03 medical and health sciences 0302 clinical medicine Apoptotic Process Neoplasms Drug Discovery polycyclic compounds Medicine Humans Cardioprotective Agent Doxorubicin 030304 developmental biology Inflammation 0303 health sciences Cardiotoxicity Antibiotics Antineoplastic business.industry technology industry and agriculture Cancer medicine.disease carbohydrates (lipids) Oxidative Stress 030220 oncology & carcinogenesis business Oxidative stress medicine.drug |
Zdroj: | Current pharmaceutical design. 25(2) |
ISSN: | 1873-4286 |
Popis: | Doxorubicin (DOX) is a cytostatic antibiotic from the class of anthracyclines widely used in chemotherapeutic cancer treatments. Despite the efficiency against several types of cancer, the use of DOX remains limited due to the side effects, especially cardiotoxicity. Among the DOX administration strategies, there are the “classic players” such as nanoparticles and polymers, which are capable of DOX delivery directly to interesting neoplastic regions. On the other hand, the “new players” such as phytochemicals and probiotics emerged with the proposal to react with DOX free radicals, reducing the oxidative stress, inflammatory and apoptotic process. Thus, this review aims to report the studies involving these classics and new players along the years that focus on improved administration and reduction of DOX-induced cardiotoxicity. |
Databáze: | OpenAIRE |
Externí odkaz: |